Every foreign manufacturer seeking a Thai FDA drug registration must appoint a Local Authorized Representative. Here is what the role covers, what Thai law requires, and how to structure the appointment correctly.
The Drug Act B.E. 2510 (1967) establishes a foundational principle: only a Thai-licensed entity may hold a drug marketing authorization or import drugs for commercial sale in Thailand. A foreign manufacturer, regardless of its regulatory standing in its home country or elsewhere, cannot be the applicant or the marketing authorization holder in a Thai FDA drug registration.
The entity that holds the marketing authorization and takes full legal responsibility for the product on the Thai market is the Local Authorized Representative (LAR), also referred to as the Marketing Authorization Holder (MAH). Before a foreign manufacturer can register any product, an LAR must be in place, holding a valid establishment license with the correct scope of activity.
A foreign-owned Thai subsidiary qualifies as an LAR provided it is incorporated in Thailand and holds the required Thai FDA establishment license. A foreign entity registered as a branch or representative office in Thailand does not qualify unless it holds its own independent establishment license.
The LAR holds two licenses: a Thai establishment license (a premises-based license issued by Thai FDA covering the entity's licensed scope of activity) and the drug marketing authorization itself, which Thai FDA issues in the LAR's name. The foreign manufacturer's name does not appear on the marketing authorization as the holder.
The LAR submits the ACTD registration dossier to Thai FDA as the named applicant. All Thai FDA queries during review are directed to the LAR. The LAR is responsible for the accuracy, completeness, and timeliness of every response. Delays or inadequate responses by the LAR extend the review timeline for the foreign manufacturer.
After approval, the LAR is responsible for variation submissions (for any approved changes to the product), marketing authorization renewal before the 7-year MA expires, Thai-language labeling accuracy, and maintaining the product information document in line with the approved specifications.
The LAR is the reporting entity for adverse drug reactions under Thai FDA's pharmacovigilance framework. Fatal or life-threatening suspected unexpected serious adverse reactions (SUSARs) must be reported within 7 calendar days. The legal exposure for late or missing reports is the LAR's, not the foreign manufacturer's, under Thai law.
The LAR oversees product distribution within Thailand, including ensuring that storage, handling, and distribution conditions meet the approved product specifications. Recalls, market withdrawals, and safety communications are initiated and managed by the LAR.
In most Thai drug registration structures, a single Thai-licensed entity serves simultaneously as the LAR (representing the foreign manufacturer) and the MAH (holding the marketing authorization). Thai FDA issues the marketing authorization to that entity as the MAH.
The distinction matters in documentation. The LAR role is defined by the foreign manufacturer's formal appointment of the Thai entity to represent it: a power of attorney or representation agreement. The MAH role is defined by Thai FDA's issuance of the marketing authorization. In practice, both labels describe the same entity in the same regulatory position.
Structures where the LAR and MAH are different entities are rare and operationally complex. Thai FDA issues the MA to a single holder; if a sub-representation arrangement exists below that, it is a commercial matter between the parties and does not change who bears the regulatory obligation to Thai FDA.
The LAR relationship is not a clerical arrangement. The LAR's regulatory competence and communication quality are reflected in every Thai FDA interaction for the lifetime of the product. The choice of LAR is the most consequential structural decision a foreign manufacturer makes when entering Thailand.
Before appointment, verify that the prospective LAR holds a current, valid establishment license with scope that covers importation and distribution of the relevant drug category. An LAR whose license is under renewal, restricted, or does not cover the correct category cannot legally hold a marketing authorization. Verification with Thai FDA directly is the only reliable check.
The LAR must be able to prepare ACTD dossiers in Thai, respond to Thai FDA technical queries, manage variation submissions, and maintain the pharmacovigilance system with documented SOPs. An LAR that outsources all technical work without maintaining meaningful oversight is a structural liability: accountability sits with the LAR regardless of who does the work.
Thai FDA correspondence is conducted in Thai. The LAR's ability to translate accurately and communicate promptly in both Thai and English determines how reliably the foreign manufacturer stays informed. An LAR that filters, delays, or softens communications to manage the relationship is a common root cause of timeline overruns that only surface after months of silence.
The written agreement between the foreign manufacturer and its LAR should clearly define who controls dossier content decisions, variation submissions, label claim authority, and recall initiation. Ambiguity in these areas leads to disputes at the worst time: during a Thai FDA review or a post-market safety event.
VeroPharma Group serves as LAR and MAH for foreign manufacturers entering the Thai pharmaceutical market. We hold the establishment licenses required for both the regulatory and importation roles and manage the full registration function in-house.
We communicate in Thai and English and give clients a clear, accurate picture of where their registration stands at every stage. When a prospective client already has a local distribution partner and needs only the regulatory LAR function, we can structure that separately. We tell clients what will and will not work before they commit.